OBJECTIVE: Premature cervical remodeling is likely an obligatory step in the pathogenesis of spontaneous preterm birth. Previously, we have shown Replens, the vehicle used to deliver vaginal progesterone, will prevent preterm birth in an inflammatory mouse model. However, it remains unknown if Replens will have an impact on cervical remodeling. Therefore, we hypothesize Replens will prevent preterm birth and cervical remodeling by inhibiting the inflammation induced functional changes to the cervical epithelial barrier. STUDY DESIGN: The integrity of the epithelial cell barrier was assessed using an in vitro permeability assay. Immortalized ectocervical cells were grown in a monolayer across a semi permeable membrane at a concentration of 2 x 10 5 cells well. Cells were treated with 10% and 25% solutions of Replens in saline for 2 hours prior to treatment with 25ug/ml of lipopolysaccharide (LPS). After 24 hours, FITCdextran was added for 2 hours. The extent of permeability was determined by measuring the fluorescence on the receiver plates well solution. RESULTS: Exposure to LPS alone significantly increased the permeability of ectocervical cells (p<0.05), and pretreatment with Replens prevented the LPS induced increase in permeability at concentrations of 10% (p<0.001) and 25% (p<0.001) compared to treatment with LPS only.
CONCLUSION: These studies demonstrate Replens prevents the LPS induced breakdown of the ectocervical epithelial barrier. Further research is needed to determine if Replens can be utilized as a therapeutic agent to prevent preterm birth.
534 Anti-granulocyte macrophage-colony stimulating factor (GM-CSF) antibody prevents the upregulation of cyclooxygenase-2 in a mouse model shown granulocyte macrophage-colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine, is upregulated in the uterus in a mouse model of preterm birth. We have also shown treatment with an antibody to GM-CSF will prevent preterm birth within six hours. Therefore, we hypothesized treatment with an antibody to GM-CSF will prevent the upregulation of contraction associated proteins in the uterus leading to preterm birth. STUDY DESIGN: For this study, we utilized a mouse model of preterm birth. On embryonic day 17, pregnant CD1 mice were anesthetized and received an intrauterine injection of lipopolysaccharide (LPS) along with either an intravenous injection of anti-mouse GM-CSF or control antibody. After six hours the uteri were harvested and analyzed for expression of the oxytocin transmembrane receptor (OXTR), cyclooxygenase-2 (COX-2), or connexin-43 (Cx43) using quantitative polymerase chain reaction (qPCR). RESULTS: LPS increased the expression of COX-2 (p<0.001) compared to mice receiving an intrauterine injection of saline, and treatment with the anti-mouse GM-CSF antibody resulted in a decreased expression of COX-2 (p<0.05). Treatment with LPS did not increase the expression of OXTR or Cx43 compared to control mice, although the GM-CSF antibody did decrease the expression of Cx43 compared to mice treated with the control antibody.
CONCLUSION: These studies demonstrate treatment with the antimouse GM-CSF antibody prevents upregulation of the contraction associated protein COX-2 in the uterus utilizing an inflammatory mouse model. Further research is needed to determine if antibodies to GM-CSF can be utilized as a therapeutic agent to prevent preterm birth. 
OBJECTIVE:
To assess the fetal neuroprotective potential of 17-hydroxyprogesterone (17OHP) and identify mechanisms for its benefit, using a novel mouse model of chronic maternal systemic inflammation. STUDY DESIGN: Using a mouse model of chronic maternal systemic inflammation involving daily intraperitoneal (IP) injections of 1mg IL-1b to CD-1 timed-pregnant dams from E15 to E18, we have previously shown that IL-1b administration results in impaired pup survival and neurodevelopmental outcomes, along with significant placental upregulation of NFkB2 and CXCL11 compared to controls. In our current experiment, CD-1 timed-pregnant dams were randomly assigned to three groups: IP phosphate buffered saline (PBS, n¼8), IP IL-1b (n¼13), or IP IL-1b + subcutaneous 17OHP (IL-1b/P, n¼10). PBS or IL-1b was administered daily from E15 to E18 with 17OHP injected 1h prior to IL-1b in randomly selected dams. Fetal brains and placentas of E18 embryos were collected 6h after final IL-1b injections and individual qPCR analyses were carried out for the following immune markers: CCL2, CCL3, CXCL9, CXCL10, CXCL11, NFkB1, NFkB2, IL-1b, IL-6, and TNFa. Additionally, flow cytometry of E18 placentas was carried out for CD3 + CD4 + and CD3 + CD8 + cells. Pups that did not undergo tissue harvesting underwent neurodevelopmental assessment at PND5 and PND9. Data were analyzed using c 2 test and ANOVA, as appropriate. RESULTS: IL-1b/P pups exhibited significantly improved performance on neurodevelopmental assessment compared IL-1b pups (Figure 1 ). QPCR analysis of immune markers in placentas revealed that 17OHP significantly reduced NFk B1 (P ¼ .0352) with a nonsignificant trend towards lower levels of IL-6 and NFkB2 (Figure 2) . Placental CD4/CD8 ratios were significantly decreased in IL-1b/P pups compared to IL-1b pups (P < .05). CONCLUSION: 17OHP improves offspring neurodevelopment in pregnant dams exposed to IL-1b-initiated chronic inflammation. Placental immunomodulation via reduction in expression of transcription factors involved in cellular responses to inflammation and reduction in inflammatory cytokines are potential mechanisms by which 17OHP confers a beneficial immunomodulatory effect on the placenta that can be neuroprotective and warrants further investigation.
536 Timing of corticosteroids for preterm premature rupture of membranes at 22 weeks: a decision analysis Clarice G. Zhou, James Sargent, Aaron B. Caughey
Oregon Health & Science University, Portland, OR OBJECTIVE: Despite their benefits, there is evidence that the effects of antenatal corticosteroids decrease 7 days after treatment, thus the timing of antenatal corticosteroids following presentation impacts neonatal outcomes. The objective of this study was to use a decision analysis to determine the optimal time for steroid administration for women with preterm premature ruptures (PPROM) of membranes at 22 weeks. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare the neonatal mortality and morbidity following antenatal corticosteroid treatment in a theoretical cohort of 1,000 women who present with PPROM at 22 weeks. The model compared administering steroids immediately at presentation (22 weeks) or in subsequent weeks (23-26 weeks gestation) following presentation. The outcomes of neonatal death, respiratory distress syndrome, intraventricular hemorrhage, and neurodevelopmental delay were assessed along with maternal and neonatal qualityadjusted life years (QALYs). All probabilities, utilities, and costs were derived from literature. Costs are expressed in 2018 US dollars with a willingness to pay threshold (WTP) set at $100,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to interrogate model assumptions. RESULTS: In our theoretical cohort of 1,000 women who present with PPROM at 22 weeks, administering antenatal corticosteroids three weeks after presentation (at 25 weeks gestation) resulted in 44
